Skyscape Web Viewer : The Maudsley Prescribing Guidelines in Psychiatry : Main Index

View All
Linaclotide, for constipation treatment
Linear reductions of dose cause increasingly large reductions in effect on GABA-A receptor occupancy.
Lipoproteins in blood, psychotropic agent effects
Lisdexamfetamine attention deficit hyperactivity disorder in adults bulimia nervosa/binge eating disorder borderline personality disorder
Lithium: prescribing and monitoring
Lithium use with
liver function tests (LFTs) interpretation monitoring to access drug effects
Lofepidrine, in overdose
Lone atrial fibrillation
Long-acting injectable antipsychotic medications - doses and frequencies
Long-acting oral antipsychotics preventing sudden cessation improving adherence restarting after period of non-compliance
Loop diuretics, lithium interaction
Lorazepam Acutely disturbed or violent behaviour catatonia treatment rapid tranquillisation of children and adolescents Catatonia concentration in normal dosing and UK legal limit use in patients with hepatic impairment
low-density lipoprotein (LDL)
Loxapine Relative adverse effects - a rough guide Smoking and psychotropic drugs
Isotretinoin, psychiatric adverse effects
Lack of engagement with psychological therapies
Legal issues
Less commonly used treatments, well supported by published evidence (no preference implied by order)
Levetiracetam, for tardive dyskinesia
Licensed maximum doses of antipsychotics, according to US Food and Drug Administration labelling, where available
Linear dose reductions of olanzapine cause increasingly large reductions in D2 dopaminergic receptor blockade.
Linear reductions of dose cause increasingly large reductions in effect on receptor targets, probably associated with more withdrawal effects.
Liraglutide, for antipsychotic-induced weight gain
Lithium: clinically relevant drug interactions
Lithium plasma levels
Lithium
Lofexidine, clozapine-induced hypersalivation
long-acting injectable (LAI)
Loperamide, safety in older patients/dementia